Navigation Links
Dartmouth researchers identify potential therapeutic target for deadly brain cancer
Date:4/8/2014

(Lebanon, NH, 4/8/14) Researchers from the Geisel School of Medicine at Dartmouth will present a scientific poster on Tuesday, April 8, 2014 at the American Association of Cancer Researchers conference in San Diego, CA. The research identifies a potential characteristic for predicting outcome in a deadly form of brain cancer known as glioblastoma multiforme.

Existing therapies based on genetic information have failed to effectively treat glioblastomas. Therefore, researchers are aggressively looking to find new molecular targets for this aggressive brain tumor.

Dartmouth researchers previously demonstrated that STK17A is a protein that is induced when DNA is damaged by the chemotherapeutic drug cisplatin. Biopsied samples of glioblastoma tumors contain high level of STK17A. And the more STK17A a tumor has the poorer the outcome appears to be. Increased levels of STK17A are correlated with shorter survival time for glioblastoma patients.

In addition, when researchers tried to "turn off" the STK17A protein, they observed a reduced rate of cancer cell growth. Reducing STK17A also interfered with tumor cells' ability to move around and invade other areas of the brain.

Further investigation is required to understand the precise role of STK17A in glioblastoma, but the finding may reveal a potential Achilles' Heel for this deadly type of brain tumor that often times seems unstoppable.


'/>"/>

Contact: Robin Dutcher
robin.Dutcher@hitchcock.org
603-653-9056
The Geisel School of Medicine at Dartmouth
Source:Eurekalert

Page: 1

Related biology news :

1. Dartmouth researchers find promising results with local hyperthermia of tumors
2. Dartmouth-led research shows temperature, not snowfall, driving tropical glacier size
3. Dartmouth study shows US Southwest irrigation system facing decline after 4 centuries
4. Dartmouth researchers develop new tool to identify genetic risk factors
5. Dartmouth-led team gets $8 million grant to research arsenic in children
6. Dartmouth-led study shows diet alone can be significant source of arsenic
7. Dartmouth-led team discovers how plants avoid sunburn
8. Dartmouth researchers find there is no single sexy chin
9. Dartmouth researchers invent real time secondhand smoke sensor
10. Dartmouth neuroscientist finds free will has neural basis
11. Dartmouth research offers new control strategies for bipolar bark beetles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... BETHESDA, Md. , June 22, 2016  The American ... by Trade Show Executive Magazine as one of ... Summit on May 25-27 at the Bellagio in ... based on the highest percentage of growth in each of ... number of exhibiting companies and number of attendees. The 2015 ...
(Date:6/22/2016)... 2016 On Monday, the Department of Homeland ... share solutions for the Biometric Exit Program. The Request ... Protection (CBP), explains that CBP intends to add biometrics ... the United States , in order to deter ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
Breaking Biology Technology: